Move For Migraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working […]
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least
Lilly Receives Positive CHMP Opinion for Emgality Read More »
Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “European Civic Prize on Chronic Pain – Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity
European Civic Prize on Chronic Pain Read More »
On Friday 7 December 2018, patient advocates and stakeholders from all world regions will stand together, united in a celebration of Patient Solidarity Day (PSD). This year’s theme is about ‘Safe Medication and Healthcare for All’ and it aims to raise awareness on these critical global public health issues and advocate for access to safe, quality and appropriate medicines
Patient Solidarity Day 2018 Read More »
INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available
Lilly’s Emgality Approved Read More »
EMHA Executive Director Mrs. Elena Ruiz de la Torre traveled to Greece yesterday September 12th on Migraine Day of Action, to assist to the meeting held at Athens by the Hellenic Headache Society on behalf of Migraine Awareness Day. She had the chance to tell her personal story about being a migraineur and how it
Hellenic Headache Society Migraine Awareness Day Read More »
How can this even be a trend!!!!???? Headache Pose? Migraine Pose? What is this supposed to mean? Migraine is not a pose but a neurological disorder involving nerve pathways and brain chemicals, which leaves completely disabled anyone who suffers an attack for an uncertain period of time. It´s very sad and outrageous that such an important
The #MigrainePose “Trend” Read More »
EMHA Executive Director Mrs. Elena Ruiz de la Torre flew the past month of August to Zurich in order to attend the first EPAC Meeting European Patient Advocacy Council F2F meeting where the topics for discussion were: 1. “Addressing inequalities in the patient voice across Europe”. 2. “Demonstrating the Impact of Patient Engagement”.
EMHA Participation at MTIS 2018: The past September 6th the European Migraine and Headache Alliance team flew all the way to London to assist to the 17th Biennial Migraine Trust International Symposium. It was an amazing and exciting event full of people interested in finding ways to give a brighter future to all migraine sufferers.
EMHA PARTICIPATION AT MTIS 2018 Read More »
Put Patients First in Headache Treatment: Stephani Sutherland, PhD, is a neuroscientist, yogi, and freelance writer in Southern California. Migraine and other severe headache disorders affect about a billion people worldwide each year, but awareness of these conditions is insufficient, and sufferers are often stigmatized by healthcare providers and by society in general. As a
Put Patients First in Headache Treatment Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
